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ABSTRACT
Objectives: Ready-to-use therapeutic food (RUTF) is the preferred treatment for uncomplicated severe acute malnutrition. It contains large amounts
of linoleic acid and little a-linolenic acid, which may reduce the availability
of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to the
recovering child. A novel high-oleic RUTF (HO-RUTF) was developed with
less linoleic acid to determine its effect on DHA and EPA status.
Methods: We conducted a prospective, randomized, double-blind clinical
effectiveness trial treating rural Malawian children with severe acute
malnutrition. Children were treated with either HO-RUTF or standard
RUTF. Plasma phospholipid fatty acid status was measured on
enrollment and after 4 weeks and compared between the 2 intervention
groups.
Results: Among the 141 children enrolled, 48 of 71 receiving HO-RUTF
and 50 of 70 receiving RUTF recovered. Plasma phospholipid samples were
analyzed from 43 children consuming HO-RUTF and 35 children
consuming RUTF. The change in DHA content during the first 4 weeks
was þ4% and 25% in the HO-RUTF and RUTF groups, respectively
(P ¼ 0.04). For EPA, the change in content was 63% and 24% in the HORUTF and RUTF groups, respectively (P < 0.001). For arachidonic acid, the
change in content was 3% and 13% in the HO-RUTF and RUTF groups,
respectively (P < 0.009).
Conclusions: The changes in DHA and EPA seen in the children treated
with HO-RUTF warrant further investigation because they suggest that

HO-RUTF support improved polyunsaturated fatty acid status, necessary for
neural development and recovery.
Key Words: docosahexaenoic acid, eicosapentaenoic acid, linolenic acid,
ready-to-use therapeutic food, severe acute malnutrition
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Conventional ready-to-use therapeutic food (RUTF)
contains high omega-6 linoleic acid and little omega3 a-linolenic acid.
Animal studies suggest that this composition reduces
neuroactive docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) status while supporting
growth.



A novel high-oleic RUTF (HO-RUTF) with less linoleic
acid showed that clinical recovery rates were similar
compared with conventional RUTF.
RUTF versus HO-RUTF caused different changes
in DHA (25% vs 4%) and EPA (24% vs 63%)
status.
HO-RUTF avoided precipitous reductions in DHA and
EPA while supporting recovery.

R

eady-to-use therapeutic food (RUTF) is the standard homebased treatment and has greatly improved the recovery rate of
children with severe acute malnutrition (SAM) in sub-Saharan
Africa (1). Conventional RUTF formulations appropriately focus
on delivery of macronutrients and essential micronutrients with
long shelf life to restore health and restart growth and development.
RUTF is a peanut paste–based food, which is rich in v-6 linoleic
acid (LA), with negligible amounts of all of the other polyunsaturated fatty acids (PUFAs), including the v-3 a-linolenic acid
(ALA) (2).
LA and ALA are substrates that are elongated and desaturated by the same enzymes (3). An excess of LA is antagonistic to
the endogenous biosynthesis and incorporation into cell membranes
of v-3 long-chain PUFAs, specifically eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA). Tissue accumulation of DHA is
essential for normal neural development, and EPA deposition in
membranes is similarly important as a balance to n-6 arachidonic
acid. More than 60 animal studies show that a dietary deficiency of
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v-3 PUFAs during neural development leads to neurocognitive
abnormalities despite normal weight and length-based growth (4).
These studies were based on a standard model of v-3 deficiency in
which rodents were fed high v-6 (LA) with v-3 (ALA) not
dissimilar to PUFA in contemporary RUTF. Additional evidence
suggests that excess LA and low ALA in protein-deficient, malnourished animals compromise neural development (5).
Recently, traditional plant breeding methods have been
applied to commodity oil-bearing crops to yield an extensive variety
of fatty acid compositions (6). A major commercial effort has been
the development of oils that have mostly replaced LA with oleic
acid. High-oleic peanuts are commercially available, and their use
in RUTF allows for large reductions of LA in RUTF.
In the present prospective, randomized, double-blind clinical
effectiveness trial, we compared standard RUTF with a high-oleic
RUTF (HO-RUTF) in the treatment of SAM. We tested the hypothesis that treatment with HO-RUTF results in greater plasma phospholipid (PL) DHA and EPA levels than that with standard RUTF.

METHODS
Patients
Malawian children with SAM aged 6 to 59 months were
recruited from 6 clinics in rural southern Malawi from January to
May 2014. Inclusion criteria were having a mid-upper arm circumference <11.5 cm and/or bilateral pitting edema, who qualify for
community-based management of SAM. Appetite was assessed by
giving the child 30 g of RUTF and requiring him/her to consume it
within 20 minutes. Exclusion criteria were treatment for SAM in the
previous 6 months, the presence of a chronic, debilitating condition
such as cerebral palsy or congenital heart disease, or peanut allergy.
human immunodeficiency virus infection was not an exclusion
criterion.
Ethical approval was obtained from the University of
Malawi, the College of William and Mary, and Washington University in St Louis.

Study Design
Children with SAM were recruited to the present prospective,
randomized, double-blind clinical effectiveness trial comparing
RUTF and HO-RUTF. The primary outcome was the change in
plasma DHA and EPA content after 4 weeks. Secondary outcomes
were rates of recovery from SAM, length and weight gain, and the
change in plasma content of arachidonic acid. Recovery from SAM
was defined as having a mid-upper arm circumference >12.4 cm
without edema within 12 weeks of enrollment.
The planned sample size for the study was 55 participants in
each study arm. This sample size allows for detection of 20%
increase in DHA and EPA in the children receiving HO-RUTF when
compared with that in children receiving RUTF, with 95% sensitivity and 80% power. This sample size estimate assumed that the
standard deviation would be 30% of the mean and 10% of the
participants would be lost to follow-up.
Patients were randomized to either RUTF or HO-RUTF by
choosing a treatment designation in a sealed envelope, prepared by a
study assistant who did not participate in the data collection or
analysis. The children, caretakers, and clinic workers were blinded
to the assigned intervention.

Participation
Given that the population is primarily communitarian and
illiterate, informed consent was obtained through a verbal, staged
www.jpgn.org
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process. Initially, village leaders and health advocates were
informed about the study through a discussion and their permission
was requested for the research team to proceed. When permission
was granted, the village health aids increased community awareness
about the study through regularly scheduled health talks, so mothers
would know that this new activity was taking place in the clinic
setting. Then, among the caretakers of eligible children, experienced pediatric nutrition nurses explained the study participation
and purpose of the study in the local language and invited the
caretakers to participate in the study. Finally, a document was
‘‘signed’’ with a fingerprint as an official record that consent
was obtained.
Initial demographic and health information was collected;
mid-upper arm circumference, length, and height were measured;
and the presence of edema was assessed on the dorsum of the feet. A
1-mL blood sample was drawn and placed in a tube with calcium
ethylenediaminetetraacetic acid. Randomization then occurred and
focused nutritional counseling and instructions on therapeutic
feeding were provided by the nurses.
Children returned every 2 weeks for a follow-up visit until
either the child recovered or 12 weeks had passed from the time of
enrollment. Anthropomorphic measurements were taken at each
visit, and caretakers were asked about their child’s health status and
feeding habits. When a child recovered, no more RUTF was given
and the child deemed to be free of acute malnutrition. At 4 weeks
after enrollment, a second blood sample was collected.

Foods
Each patient was given a quantity of RUTF that provided
approximately 175 kcal/kg/day (735 kJ/kg/day). Standard RUTF
was made with peanuts, palm oil, and soy oil, whereas HO-RUTF
was made with high-oleic peanut, palm oil, and linseed oil (Table 1).
The fatty acid content of the HO-RUTF contained more ALA and
less LA than that of the RUTF (Table 1). Other than the fatty acid
content, the nutrient content of the study foods was similar (Table
S1, http://links.lww.com/MPG/A432). Each patient was given a
ration sufficient for 2 weeks.
RUTF was produced by Project Peanut Butter in Blantyre,
Malawi, and the HO-RUTF was produced by Nutriset (Malaunay,
France). Both RUTF products passed safety testing for aflatoxin and
microbial contamination (Malawi Bureau of Standards and Eurofins
Scientific Inc, Des Moines, IA).
Caretakers were instructed to feed their children the entire
ration of RUTF during the 2-week period. Well-nourished twins
were given a RUTF ration to limit sharing of RUTF within households. Participants who lived in the same household received the
same food to prevent confounding.

Acceptability Trial
Before the trial, a double-blind acceptability trial of HORUTF with 148 Malawian children from 6 months to 5 years of age
with SAM was conducted during June to August 2013. Each child
was randomly assigned to receive either the standard RUTF or HORUTF.
The acceptability trial involved 2 components. All of the 148
children were given 30 g of the assigned food, and the time to
consume all of the food was measured. If all of the food was not
consumed after 40 minutes or the child stopped eating, the remaining food was weighed and time recorded. Caretakers then completed a survey that assessed each child’s appetite and likeability of
the food.
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TABLE 1. Ingredient composition and fatty acid content of ready-to use study foods
Ingredient
Ready-to-use therapeutic food, %
Dry skimmed milk
Sweet whey
Peanuts
Linseed oil
Palm oil
Soy oil
Sugar and maltodextrin
Micronutrients and monoglyceride and diglyceride emulsifier
Fatty acid content

Saturated fat
Monounsaturated fat
LA
ALA
LA:ALA ratio
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High-oleic ready-to-use therapeutic food, %

25
0
27
0
15.8
2.9
26
3.2

17.2
14.5
24.6
8.2
13.0
0
19.0
3.3

Ready-to-use therapeutic food

High-oleic ready-to-use therapeutic food

Fraction

Amount g/100 g

Fraction

Amount, g/100 g

37.2%
41.1%
21.3%
0.4%
53:1

15.7
17.4
8.9
0.17

28.7%
44.7%
13.1%
13.1%
1:1

10.1
15.8
4.4
4.4

ALA ¼ a-linolenic acid; LA ¼ linoleic acid.

The second stage of the acceptability trial was conducted
with a subset of 57 children from the first stage, 29 children
receiving HO-RUTF and 28 children receiving RUTF. These children were provided with 90 g of the assigned food for each day for 3
days, and consumption was monitored by their caretaker. On the
fourth day, participants returned and caretakers completed a final
likeability survey.

other covariates included whether the mother was the child’s
primary caretaker, baseline anthropometric measurements, and
human immunodeficiency virus status of the mother and the child.
Covariates were considered significant if P < 0.05.

RESULTS
Study Patients

Fatty Acid Analysis
Plasma from blood samples drawn into ethylenediaminetetraacetic acid tubes was separated, frozen, and maintained at
<208C for transport to the Brenna laboratory (Ithaca, NY). All
of the samples that were received intact were analyzed in a blinded
fashion, and no data were excluded from the statistical analyses.
Plasma PLs were separated by thin layer chromatography, and fatty
acid profiles were measured by gas chromatography (GC) after
derivation to fatty acid methyl esters with BF3 in methanol (7–9).
Capillary GC with flame ionization detection was used to detect the
esters, with calibration based on an equal weight standard run daily
to establish response factors, as well as heptadecanoic acid internal
standard for quality control. Fatty acid identities were periodically
checked by GC–covalent adduct chemical ionization mass spectrometry.

Data Analysis
Clinical data were entered into a Microsoft Access database,
cleaned, and kept blinded throughout the analyses. Summary
statistics were calculated for each dietary group, including plasma
PL fatty acid content. Fatty acid content was expressed as grams per
100 g lipid. The difference in fatty acid content for the 2 dietary
groups was calculated from enrollment to 4 weeks. Student t test
was used to compare continuous outcomes after passing a test of
normality (Shapiro-Wilk test with P > 0.1), and Fisher exact test
was used to compare categorical outcomes (SPSS 22.0; IBM,
Chicago, IL). Differences were considered significant if P < 0.05.
Binary logistic regression modeling was used to predict
recovery. The type of RUTF was the primary independent variable;
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A total of 141 children were enrolled from January to May
2014 (Table 2; Fig. S1, http://links.lww.com/MPG/A433). No
adverse reactions to any of the study foods were reported. After
randomization, 70 children were assigned to RUTF and 71 children
were assigned to HO-RUTF. Both initial and 4-week blood samples
were analyzed from 78 children, 35 receiving RUTF and 43
receiving HO-RUTF. No differences were detected in any plasma
PL fatty acids between the 2 dietary groups at enrollment (P > 0.15;
Table S2, http://links.lww.com/MPG/A434).

Acceptability Trial
Likeability on the first day for both the first and the second
components showed a score of 5, highest on the scale, for 64 of 74
participants receiving RUTF and 59 of 74 receiving HO-RUTF
(P ¼ 0.38). On day 4 of the acceptability survey in the second
component of the trial, all of the participants reported a likeability
score of 5. During the first activity of the acceptability trial, children
consumed 30 g of standard RUTF in 9.3 minutes and 30 g of HORUTF in 12.3 minutes. In the second activity, standard RUTF and
HO-RUTF consumption took 10.4 and 12.8 minutes, respectively.
The amount of food remaining at the end of the taste test was greater
among the HO-RUTF food taste testers than that among the
standard RUTF tasters in both components (3.7  8.0 vs
1.3  4.6 g, P ¼ 0.03).

Clinical Outcomes
The overall recovery rate for children receiving RUTF was
71% and 68% for children receiving HO-RUTF (P ¼ 0.72; Table 3).
Binary logistic regression modeling also confirmed that the type of
www.jpgn.org
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TABLE 2. Characteristics of children on enrollment

Ready-to-use therapeutic food
N ¼ 70

High-oleic ready-to-use therapeutic food
N ¼ 71

19  9.7
25 (36)
33 (47)
66 (94)
8 (11)
44 (63)
12.0  1.2
1.8  1.1
2.9  1.4
N ¼ 40
3.2  1.6
0.7  0.7
0.4  0.3
15.6  3.5

20  13
27 (38)
33 (46)
66 (93)
2 (3)
41 (58)
11.8  1.3
1.9  1.0
3.3  1.7
N ¼ 41
2.8  1.4
0.7  0.7
0.3  0.3
14.7  4.3

Age, mo
Males
Presently breast-feeding
Primary caregiver was mother
Mother was HIV positive
Edematous malnutrition
Mid-upper arm circumference, cm
Weight-for-height, z score
Height-for-age, z score
Plasma phospholipid content
Docosahexaenoic acid, % weight of lipid
Eicosapentaenoic acid, % weight of lipid
a-Linolenic acid, % weight of lipid
Linoleic acid, % weight of lipid
HIV ¼ human immunodeficiency virus; SD ¼ standard deviation.

Values are means  SD or n (%).

RUTF administered did not predict recovery. Children receiving
HO-RUTF had a greater weight-for-height z score on completion of
therapy (P ¼ 0.02).

Plasma PL Fatty Acids
Plasma PL EPA levels were higher and arachidonic acid was
lower in children who received HO-RUTF, compared with those in
children who received RUTF (Table 3). DHA levels decreased by
25% after 4 weeks from enrollment in the standard RUTF group, but
did not change significantly in the HO-RUTF group, whereas
opposite changes were seen in arachidonic acid and docosapentaenoic acid n-6 (DPAn-6; Fig. 1). EPA and docosapentaenoic acid n-3
(DPAn-3) increased during 4 weeks in the HO-RUTF group,
whereas DHA did not change (Table S2, http://links.lww.com/
MPG/A434).

TABLE 3. Clinical outcomes

DISCUSSION
Children with SAM treated with conventional RUTF demonstrated a relative reduction in v-3 long-chain PUFA status, compared with children treated with HO-RUTF after 4 weeks of
treatment. HO-RUTF led to relative increases of þ29% and
þ87% for DHA and EPA, respectively. Anthropometric recovery
and growth rates were similar between the 2 groups, and thus this
shows that the HO-RUTF does not compromise physical recovery.
More important, the effectiveness of high LA/low ALA in supporting growth and recovery is consistent with much animal data
showing normal growth but severe neurological abnormalities in
similarly LA-dominant diets (4).
The small sample size limited our ability to detect differences
in recovery of <10%, and the study design did not assess developmental outcomes. The participants were rural African children
consuming a plant-based diet, and the findings cannot necessarily



Clinical outcomes, n (%)
Recovered
Remained malnourished
Lost to follow-up
Died
MUAC gain after 4 wk, mm/day
Weight gain after 4 wk, g/kg/day
Length gain at study completion, mm/day
Weight-for-height at recovery, z score
Plasma PL fatty acid, % (w/w) after 4 wk
DHA
EPA
ALA
LA
Arachidonic acid

Ready-to-use therapeutic food
N ¼ 70

High-oleic ready-to-use therapeutic food
N ¼ 71

50 (71)
9 (13)
6 (9)
5 (7)
0.15  0.28
2.0  2.6
0.13  0.36
0.60  1.0
N ¼ 35
2.4  1.1
0.5  0.6
0.7  1.1
17.3  6.5
7.6  3.7

48 (68)
19 (27)
3 (4)
1 (1)
0.22  0.31
2.8  3.1
0.22  0.34
0.15  1.3
N ¼ 43
3.0  1.5
1.1  0.8
0.8  0.8
16.3  5.7
5.6  3.2

P
0.72

0.20
0.41
0.22
0.02
0.04
<0.001
0.53
0.43
<0.01

ALA ¼ a-linolenic acid; DHA ¼ docosahexaenoic acid; EPA ¼ eicosapentaenoic acid; LA ¼ linoleic acid; MUAC ¼ mid-upper arm circumference;
PL ¼ phospholipid; SD ¼ standard deviation.

Values are means  SD or n (%).

www.jpgn.org
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1.0

FA, change from entry (% weight)

HO (low LA)
0.5

Conventional

*

*

*

0.0
P = 0.06
–0.5

–1.0

–1.5

A

DPAn-6

EPA

DPAn-3

DHA

FA, change from entry (percentage
of pooled entry)

120
100

HO (low LA)
All P < 0.05

Conventional
80
60
40
20
0
–20
–40
–60

B

DPAn-6

EPA

DPAn-3

DHA

FIGURE 1. Changes in plasma fatty acids after receiving 4 weeks of HO-RUTF or RUTF. (A) Change expressed in percentage by weight of fatty acid,
showing HO-RUTF induces a slight reduction in DPAn-6 and increases in the v-3 long-chain PUFAs EPA and DHA. In contrast, treatment with
conventional RUTF led to an increase in DPAn-6 and a decrease in DHA. (B) Changes expressed as percentage of the pooled means demonstrate

the most significant percentage change was in EPA. The symbol ‘‘ ’’ indicates that the difference between the RUTFs was P < 0.05 (using Excel
2003, build 11.5612.5606). Means  95% CI. EPA, DPAn-3, and DHA changes are normally distributed by Shapiro-Wilk test (P > 0.1); DPAn-6
evaluated by t test (P ¼ 0.0002). CI ¼ confidence interval; DHA ¼ docosahexaenoic acid; DPAn-3 ¼ docosapentaenoic acid n-3; DPAn6 ¼ docosapentaenoic acid n-6; EPA ¼ eicosapentaenoic acid; FA ¼ fatty acid; HO-RUTF ¼ high-oleic RUTF; LA ¼ linoleic acid; PUFA ¼ polyunsatupolyunsaturated fatty acid; RUTF ¼ ready-to-use therapeutic food.

be generalized to urban settings, outside of Africa and to other
populations with greater breast milk DHA content and other dietary
differences. Our findings may also not be generalizable to populations with considerable fish consumption, especially salmonids
and other fatty fish, which are known to increase breast milk EPA
and DHA. Another limitation of the study was that the 4-week
period between the first and the second blood sampling was not
enough time to change erythrocyte fatty acid content; thus, only the
short-term plasma PL content was measured.
The clinical importance of these results as related to neurodevelopmental function is uncertain because of the paucity of
research on DHA in malnutrition. A recent study in rats showed
that protein malnutrition compromises brain DHA, and that brain
DHA can be improved by increasing DHA in rat milk (5). If these
results apply to humans, the importance of nutritional DHA support
via reduced LA and/or supplemental DHA is all the more critical.
DHA and EPA status have known and emerging neurophysiological implications. Development of neural tissue requires a
steady supply of DHA during the brain growth spurt, which in well-

142

nourished children starts at approximately week 27 of gestation and
continues through 2 years of age (10). Compromise of plasma PL
DHA is particularly worrisome in light of data indicating that a
major route of entry of DHA to the brain is as lysophosphatidylcholine mediated by a recently identified protein transporter (11,12). A
plausible interpretation of our results is that the dramatic drop in
plasma PL DHA is caused in part by central nervous system DHA
demand outpacing hepatic DHA synthesis as SAM subsides and
growth and development restart. DHA and EPA metabolites are
well known to have anti-inflammatory effects via signaling eicosanoids and docosanoids (13). The increase in circulating EPA
induced by the HO-RUTF compared with that by the standard
RUTF would be expected to be especially significant as a balance to
arachidonic acid, which was increased in the standard RUTF, but
decreased in HO-RUTF. Emerging data show that DHA and EPA
are antinociceptic signaling epoxides, and our previous data show
that circulating vicinal diols, the excreted forms of these metabolites, are higher in developing animals that have better DHA status
(14,15).
www.jpgn.org
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Endogenous DHA synthesis needed for neurodevelopment is
particularly vulnerable to excess LA. Two-dozen studies in adult
humans now show that raising dietary ALA, or indeed any precursor
including EPA, does not increase circulating levels of DHA (16).
The rate-limiting desaturase coded by the FADS2 gene has numerous substrates competing with one another for D6 and D8 desaturation. Endogenous synthesis of DHA uses the FADS2 desaturase
twice: once for insertion of the double bond at eventual position 10
via D6 desaturation of 18:3n-3 ! 18:4n-3 (ALA ! 18:4n-3) and
once for insertion of the double bond at position 4 by D6 desaturation of 24:5n-3 ! 24:6n-3 or direct D4 desaturation of 22:5n3 ! 22:6n-3 (DPAn-3 ! DHA), as is the case in some vertebrates
and as we have recently presented for human cells (17,18). As a
result, excess LA inhibits endogenous synthesis of DHA, as well as
its incorporation into membranes.
The HO-RUTF studied here was formulated to provide a
similar quantity of nutrients as are included in standard RUTF and
to test the hypothesis that large excesses of LA alter DHA status.
The precise composition of HO-RUTF was not optimized for
endogenous DHA synthesis because the amounts of LA and
ALA remain high. Both LA and ALA are substrates for the FADS2
desaturase, antagonizing the insertion of the last double bond into
DHA. This leads to the superficially counterintuitive but mechanistically well understood result that high LA, high ALA, or both
reduce endogenous DHA synthesis (19). In mice, plasma PL DHA
is maximal when dietary ALA and LA account for approximately
2% of fatty acids (20). At any particular proportion (or ratio) of
ALA and LA, ALA levels >2% cause a decrease in plasma DHA;
this phenomenon is independent of total fat as a percentage of
energy and depends only on the relative amounts of ALA and LA in
fat. In HO-RUTF, they are approximately 13%, suggesting that
lower amounts of ALA and LA will boost endogenous DHA
synthesis. This quantity and proportion of ALA and LA would
be obtained in a diet in which the majority of fat is obtained from
edible leaves, such as spinach and cabbage, in which ALA predominates over LA, but which both provide only a small fraction of
the total energy intake. This pattern of fatty acid consumption was
routine in the preindustrial diet.
Future research to confirm and extend these preliminary
results should include a larger clinical trial investigating HO-RUTF
with measures of cognitive outcome. An alternative strategy to
improve long-chain PUFA status is to supplement EPA and DHA
directly. EPA–DHA-containing oils, however, are the most labile
of food ingredients, and care is necessary to avoid introducing offflavors during formulation and storage, thus increasing production
cost and reducing shelf life. In contrast, high-oleic oils are no more
expensive to produce and are more shelf stable than conventional
commodity counterparts. It is for this reason that industrial production of high-oleic edible oils has increased dramatically in recent
years; for instance, most US sunflower oil is high oleic, and soy oil,
presently supplying >15% of calories in the United States, is
projected to be approximately 40% high oleic by 2020 (21).
High-oleic peanuts are widely available in food products in Australia and production in the United States is expanding. Finally, no
inherent incompatibility exists in supplementing HO-RUTF with
EPA and DHA oils, should that step be desirable on a commercial
scale.
In conclusion, the effectiveness of HO-RUTF was similar to
that of standard RUTF in achieving anthropometric recovery in
SAM. Children who consumed HO-RUTF better maintained their
DHA and EPA content in plasma PL when compared with the
children consuming standard RUTF. This observation, in conjunction with what is known about DHA and EPA biosynthesis, questions whether PUFAs in RUTF are optimized for neurocognitive
recovery.
www.jpgn.org
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